価格表

在庫・価格 : 2019年07月22日 19時08分 現在

商品名 商品コード メーカー 包装 価格 在庫 リスト
Anti-LRRK2, Rabbit-Poly <Anti-Leucine-Rich Repeat Kinase 2>
データシート
NB300-268 NOVノバス バイオロジカルス
Novus biologicals, LLC
0.1 ml ¥64,000
キャンペーン
¥51,200

(未発注)
追加

在庫・価格 : 2019年07月22日 19時08分 現在

Anti-LRRK2, Rabbit-Poly <Anti-Leucine-Rich Repeat Kinase 2>

  • 商品コード:NB300-268
  • メーカー:NOV
  • 包装:0.1ml
  • 価格: ¥64,000 キャンペーン ¥51,200
  • 在庫:無(未発注)
使用文献
No. 文献情報 備考 参照
1 Miklossy J et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006 Oct;65(10):953-63
Miklossy J et al
2006/01/01
PubMed
2 Melrose HL et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007 Jul;147(4):1047-58
Melrose HL et al
2007/01/01
Western Blot, Immunohistochemistry PubMed
3 Alegre-Abarrategui J et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009 Nov;18(21):4022-34
Alegre-Abarrategui J et al
2009/01/01
PubMed
4 Venderova K et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson''s disease. Hum. Mol. Genet. 2009 Nov;18(22):4390-404
Venderova K et al
2009/01/01
PubMed
5 Liu Z et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011 Nov;12(11):1063-70
Liu Z et al
2011/01/01
PubMed
6 Ito G et al. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 2012 Feb;441(3):987-94
Ito G et al
2012/01/01
PubMed
7 Saha S et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009 Jul;29(29):9210-8
Saha S et al
2009/01/01
PubMed
8 Hatano T et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007 Mar;16(6):678-90
Hatano T et al
2007/01/01
PubMed
9 Santpere G et al. LRRK2 and neurodegeneration. Acta Neuropathol. 2009 Mar;117(3):227-46
Santpere G et al
2009/01/01
PubMed
10 Hakimi M et al. Parkinson''s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011 May;118(5):795-808
Hakimi M et al
2011/01/01
Applications: WB, Species: Human, Mouse PubMed
11 Hermann A et al. Reduced LRRK2-positive neurons in the striatum of Parkinson窶冱 disease patients hypothesize a retrograde disease mechanism? . Basal Ganglia http://dx.doi.org/10.1016/j.baga.2012.04.030. 2012. (IHC and IHC, IF, Human)

Species: Human, Applications: IHC and IHC, IF PubMed
12 Pandey N et al. Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death. PLoS ONE 2012;7(9):e45149
Pandey N et al
2012/01/01
Applications: WB PubMed
13 Yao C et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson''s disease. Neurobiol. Dis. 2010 Oct;40(1):73-81
Yao C et al
2010/01/01
Species: C. elegans, Applications: IHC, ICC/IF, WB PubMed
14 Marker DF et al. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 2012;9:261
Marker DF et al
2012/01/01
Species: Mouse, Applications: ICC/IF PubMed
15 Qing H et al. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009 Dec;390(4):1229-34
Qing H et al
2009/01/01
Species: Human, Applications: IHC, ICC/IF PubMed
16 Kamikawaji S et al. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009 Nov;48(46):10963-75
Kamikawaji S et al
2009/01/01
Species: Human, Moth, Applications: IP, WB PubMed
17 Greggio E et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem. 2007 Jul;102(1):93-102
Greggio E et al
2007/01/01
Species: Human, Applications: WB PubMed
18 Kamikawaji S et al. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Biochemistry 2013 Sep;52(35):6052-62
Kamikawaji S et al
2013/01/01
Species: Human, Applications: WB PubMed
19 Sekigawa A et al. Distinct mechanisms of axonal globule formation in mice expressing human wild type &#x3B1;-synuclein or dementia with Lewy bodies-linked P123H &#x3B2;-synuclein. Mol Brain 2012;5:34
Sekigawa A et al
2012/01/01
PubMed
20 Angeles DC et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum. Mol. Genet. 2014 Jun;23(12):3157-65
Angeles DC et al
2014/01/01
Species: Human, Applications: WB PubMed
21 Chan SL et al. MAP1B rescues LRRK2 mutant-mediated cytotoxicity. Mol Brain 2014;7:29
Chan SL et al
2014/01/01
Species: Human, Applications: ICC/IF, WB PubMed
22 Gaig C et al. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J. Neurol. Sci. 2008 Jul;270(1-2):94-8
Gaig C et al
2008/01/01
Species: Human PubMed
23 Waxman EA et al. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J. Neuropathol. Exp. Neurol. 2009 Jul;68(7):785-96
Waxman EA et al
2009/01/01
Species: Human PubMed
24 Alegre-Abarrategui J et al. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson''s disease. Neuropathol. Appl. Neurobiol. 2007 Oct;
Alegre-Abarrategui J et al
2007/01/01
Species: Human PubMed
25 Ludolph AC et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 2009 Mar;16(3):297-309
Ludolph AC et al
2009/01/01
Species: Human PubMed
26 Ito G et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson''s disease. Biochemistry 2007 Feb;46(5):1380-8
Ito G et al
2007/01/01
Species: Human PubMed
27 Miklossy J et al. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol. 2007 Sep;114(3):243-54
Miklossy J et al
2007/01/01
Species: Human PubMed
28 Nucifora FC et al. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun 2016;7:11792
Nucifora FC et al
2016/01/01
PubMed
29 Sheng D et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 2010 Apr;6(4):e1000914
Sheng D et al
2010/01/01
PubMed
30 Higashi S et al. Localization of Parkinson''s disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007 Jun;1155:208-19
Higashi S et al
2007/01/01
PubMed
31 Zhu X et al. LRRK2 in Parkinson''s disease and dementia with Lewy bodies. Mol Neurodegener 2006;1:17
Zhu X et al
2006/01/01
PubMed
32 Zhu X et al. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 2006 Nov;60(5):617-8; author reply 618-9
Zhu X et al
2006/01/01
PubMed
33 Bliederhaeuser C et al. LRRK2 contributes to monocyte dysregulation in Parkinson''s disease. Acta Neuropathol Commun 2016 11;4(1):123
Bliederhaeuser C et al
2016/01/01
Species: Human, Applications: FLOW PubMed
  • No.: 1
  • 文献情報:
    Miklossy J et al. LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 2006 Oct;65(10):953-63
    Miklossy J et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 2
  • 文献情報:
    Melrose HL et al. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 2007 Jul;147(4):1047-58
    Melrose HL et al
    2007/01/01
  • 備考:
    Western Blot, Immunohistochemistry
  • 参照:
    PubMed
  • No.: 3
  • 文献情報:
    Alegre-Abarrategui J et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum. Mol. Genet. 2009 Nov;18(21):4022-34
    Alegre-Abarrategui J et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 4
  • 文献情報:
    Venderova K et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson''s disease. Hum. Mol. Genet. 2009 Nov;18(22):4390-404
    Venderova K et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 5
  • 文献情報:
    Liu Z et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011 Nov;12(11):1063-70
    Liu Z et al
    2011/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 6
  • 文献情報:
    Ito G et al. Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form. Biochem. J. 2012 Feb;441(3):987-94
    Ito G et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 7
  • 文献情報:
    Saha S et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009 Jul;29(29):9210-8
    Saha S et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 8
  • 文献情報:
    Hatano T et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 2007 Mar;16(6):678-90
    Hatano T et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 9
  • 文献情報:
    Santpere G et al. LRRK2 and neurodegeneration. Acta Neuropathol. 2009 Mar;117(3):227-46
    Santpere G et al
    2009/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 10
  • 文献情報:
    Hakimi M et al. Parkinson''s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 2011 May;118(5):795-808
    Hakimi M et al
    2011/01/01
  • 備考:
    Applications: WB, Species: Human, Mouse
  • 参照:
    PubMed
  • No.: 11
  • 文献情報:
    Hermann A et al. Reduced LRRK2-positive neurons in the striatum of Parkinson窶冱 disease patients hypothesize a retrograde disease mechanism? . Basal Ganglia http://dx.doi.org/10.1016/j.baga.2012.04.030. 2012. (IHC and IHC, IF, Human)

  • 備考:
    Species: Human, Applications: IHC and IHC, IF
  • 参照:
    PubMed
  • No.: 12
  • 文献情報:
    Pandey N et al. Sequences Located within the N-Terminus of the PD-Linked LRRK2 Lead to Increased Aggregation and Attenuation of 6-Hydroxydopamine-Induced Cell Death. PLoS ONE 2012;7(9):e45149
    Pandey N et al
    2012/01/01
  • 備考:
    Applications: WB
  • 参照:
    PubMed
  • No.: 13
  • 文献情報:
    Yao C et al. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson''s disease. Neurobiol. Dis. 2010 Oct;40(1):73-81
    Yao C et al
    2010/01/01
  • 備考:
    Species: C. elegans, Applications: IHC, ICC/IF, WB
  • 参照:
    PubMed
  • No.: 14
  • 文献情報:
    Marker DF et al. LRRK2 kinase inhibition prevents pathological microglial phagocytosis in response to HIV-1 Tat protein. J Neuroinflammation 2012;9:261
    Marker DF et al
    2012/01/01
  • 備考:
    Species: Mouse, Applications: ICC/IF
  • 参照:
    PubMed
  • No.: 15
  • 文献情報:
    Qing H et al. Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease. Biochem. Biophys. Res. Commun. 2009 Dec;390(4):1229-34
    Qing H et al
    2009/01/01
  • 備考:
    Species: Human, Applications: IHC, ICC/IF
  • 参照:
    PubMed
  • No.: 16
  • 文献情報:
    Kamikawaji S et al. Identification of the autophosphorylation sites of LRRK2. Biochemistry 2009 Nov;48(46):10963-75
    Kamikawaji S et al
    2009/01/01
  • 備考:
    Species: Human, Moth, Applications: IP, WB
  • 参照:
    PubMed
  • No.: 17
  • 文献情報:
    Greggio E et al. Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem. 2007 Jul;102(1):93-102
    Greggio E et al
    2007/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 18
  • 文献情報:
    Kamikawaji S et al. Differential effects of familial parkinson mutations in LRRK2 revealed by a systematic analysis of autophosphorylation. Biochemistry 2013 Sep;52(35):6052-62
    Kamikawaji S et al
    2013/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 19
  • 文献情報:
    Sekigawa A et al. Distinct mechanisms of axonal globule formation in mice expressing human wild type &#x3B1;-synuclein or dementia with Lewy bodies-linked P123H &#x3B2;-synuclein. Mol Brain 2012;5:34
    Sekigawa A et al
    2012/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 20
  • 文献情報:
    Angeles DC et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum. Mol. Genet. 2014 Jun;23(12):3157-65
    Angeles DC et al
    2014/01/01
  • 備考:
    Species: Human, Applications: WB
  • 参照:
    PubMed
  • No.: 21
  • 文献情報:
    Chan SL et al. MAP1B rescues LRRK2 mutant-mediated cytotoxicity. Mol Brain 2014;7:29
    Chan SL et al
    2014/01/01
  • 備考:
    Species: Human, Applications: ICC/IF, WB
  • 参照:
    PubMed
  • No.: 22
  • 文献情報:
    Gaig C et al. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J. Neurol. Sci. 2008 Jul;270(1-2):94-8
    Gaig C et al
    2008/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 23
  • 文献情報:
    Waxman EA et al. Leucine-rich repeat kinase 2 expression leads to aggresome formation that is not associated with alpha-synuclein inclusions. J. Neuropathol. Exp. Neurol. 2009 Jul;68(7):785-96
    Waxman EA et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 24
  • 文献情報:
    Alegre-Abarrategui J et al. LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson''s disease. Neuropathol. Appl. Neurobiol. 2007 Oct;
    Alegre-Abarrategui J et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 25
  • 文献情報:
    Ludolph AC et al. Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur. J. Neurol. 2009 Mar;16(3):297-309
    Ludolph AC et al
    2009/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 26
  • 文献情報:
    Ito G et al. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson''s disease. Biochemistry 2007 Feb;46(5):1380-8
    Ito G et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 27
  • 文献情報:
    Miklossy J et al. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol. 2007 Sep;114(3):243-54
    Miklossy J et al
    2007/01/01
  • 備考:
    Species: Human
  • 参照:
    PubMed
  • No.: 28
  • 文献情報:
    Nucifora FC et al. Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nat Commun 2016;7:11792
    Nucifora FC et al
    2016/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 29
  • 文献情報:
    Sheng D et al. Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect. PLoS Genet. 2010 Apr;6(4):e1000914
    Sheng D et al
    2010/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 30
  • 文献情報:
    Higashi S et al. Localization of Parkinson''s disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007 Jun;1155:208-19
    Higashi S et al
    2007/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 31
  • 文献情報:
    Zhu X et al. LRRK2 in Parkinson''s disease and dementia with Lewy bodies. Mol Neurodegener 2006;1:17
    Zhu X et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 32
  • 文献情報:
    Zhu X et al. LRRK2 protein is a component of Lewy bodies. Ann. Neurol. 2006 Nov;60(5):617-8; author reply 618-9
    Zhu X et al
    2006/01/01
  • 備考:
  • 参照:
    PubMed
  • No.: 33
  • 文献情報:
    Bliederhaeuser C et al. LRRK2 contributes to monocyte dysregulation in Parkinson''s disease. Acta Neuropathol Commun 2016 11;4(1):123
    Bliederhaeuser C et al
    2016/01/01
  • 備考:
    Species: Human, Applications: FLOW
  • 参照:
    PubMed